Related Experiment Video
Updated: Mar 6, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Knockdown of GATAD2A suppresses cell proliferation in thyroid cancer in vitro
Zongping Wang1, Jie Kang1, Xianzhao Deng1
1Department of General Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, P.R. China.
Abstract:
GATAD2A (GATA zinc finger domain containing 2A), is a subunit of NuRP (nucleosome remodeling and histone deacetylation) which plays key roles in tumor growth inhibition and embryonic development. However, its role in thyroid cancer remains unclear. In our study, we established two thyroid cancer cell lines by lentivirus-delivered short hairpin (shRNA) to knockdown the expression of GATAD2A. Then loss-of-function assays indicated that knockdown of GATAD2A decreased the ability of cell proliferation and colony formation in thyroid cancer cells by MTT and colony formation assay, respectively. Moreover, cell cycle assay by flow cytometry revealed that the percentage of cells in G0/G1 phase was significantly decreased in GATAD2A knockdown cells accompanied by increase of cells in G2/M phase. Furthermore, inhibition of GATAD2A promoted cell apoptosis via elevating the expression of caspase-3 and PARP cleavage using Annexin V/7-AAD double staining and western blotting. In conclusion, GATAD2A is an essential factor in thyroid cancer cell growth and apoptosis, and may be a potential therapeutic biomarker in thyroid cancer.
Insights
GATAD2A knockdown inhibits thyroid cancer cell growth and colony formation. This study reveals GATAD2A
Area of Science:
- Oncology
- Molecular Biology
Background:
- GATA zinc finger domain containing 2A (GATAD2A) is a NuRP subunit involved in tumor growth and development.
- Its specific role in thyroid cancer pathogenesis is not well understood.
Purpose of the Study:
- To investigate the function of GATAD2A in thyroid cancer cell proliferation, cell cycle, and apoptosis.
- To assess the potential of GATAD2A as a therapeutic target or biomarker in thyroid cancer.
Main Methods:
- Thyroid cancer cell lines were established with GATAD2A knockdown using lentivirus-delivered short hairpin RNA (shRNA).
- Loss-of-function assays included MTT and colony formation assays to evaluate proliferation and colony formation.
- Cell cycle analysis was performed using flow cytometry.
- Apoptosis was assessed via Annexin V/7-AAD staining and Western blotting for caspase-3 and PARP cleavage.
Main Results:
- GATAD2A knockdown significantly reduced thyroid cancer cell proliferation and colony formation.
- Knockdown cells exhibited a decreased percentage in the G0/G1 phase and an increased percentage in the G2/M phase of the cell cycle.
- Inhibition of GATAD2A promoted apoptosis, evidenced by increased caspase-3 and PARP cleavage.
Conclusions:
- GATAD2A plays a crucial role in regulating thyroid cancer cell growth and survival.
- GATAD2A is a potential therapeutic biomarker for thyroid cancer, warranting further investigation for targeted therapies.
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

